Horizon Therapeutics Public Limited Company (HZNP) |
|
109.17 0.65 (0.6%)
|
03-27 16:00 |
|
Open: |
108.85 |
Pre. Close: |
108.52 |
|
High:
|
109.26 |
Low:
|
108.625 |
|
Volume:
|
1,689,853 |
Market Cap:
|
24,940(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:20:04 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 128.04 One year: 129.72 |
| Support: |
Support1: 107.3 Support2: 89.27 |
| Resistance: |
Resistance1: 109.62 Resistance2: 111.06 |
| Pivot: |
109.16  |
| Moving Average: |
MA(5): 108.4 MA(20): 109.36
MA(100): 103.01 MA(250): 89.01 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 40.9 %D(3): 25.3 |
| RSI: |
RSI(14): 48.8 |
| 52-week: |
High: 117.48 Low: 57.84 |
| Average Vol(K): |
3-Month: 2,438 (K) 10-Days: 1,667 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HZNP ] has closed below upper band by 49.8%. Bollinger Bands are 75.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
109.39 - 109.81 |
109.81 - 110.23 |
|
Low:
|
107.5 - 108.01 |
108.01 - 108.53 |
|
Close:
|
108.35 - 109.13 |
109.13 - 109.91 |
|
Company Description |
|
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany. |
Headline News |
Mon, 27 Mar 2023
Access Financial Services Inc. Acquires Shares of 3708 Horizon ... - MarketBeat
Thu, 23 Mar 2023
Horizon Therapeutics Public Limited receives a $30.83 million ... - Best Stocks
Thu, 23 Mar 2023
Should You Invest in Horizon Therapeutics Public Limited Company (HZNP)? - Yahoo Finance
Thu, 16 Mar 2023
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Horizon ... - Benzinga
Thu, 16 Mar 2023
Should You Invest in the SPDR S&P Biotech ETF (XBI)? - Nasdaq
Tue, 14 Mar 2023
Alliancebernstein L.P. Grows Position in Horizon Therapeutics ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
228 (M) |
| Shares Float |
226 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
92.6 (%) |
|
Shares Short
|
3,260 (K) |
|
Shares Short P.Month
|
3,420 (K) |
Stock Financials |
|
EPS
|
2.21 |
|
EPS Est Next Qtl
|
0.23 |
|
EPS Est This Year
|
1.07 |
|
EPS Est Next Year
|
1.25 |
|
Book Value (p.s.)
|
22.31 |
|
Profit Margin (%)
|
14.3 |
|
Operating Margin (%)
|
22.5 |
|
Return on Assets (ttm)
|
5.7 |
|
Return on Equity (ttm)
|
10.6 |
|
Qtrly Rev. Growth
|
-7.1 |
|
Gross Profit (p.s.)
|
12.25 |
|
Sales Per Share
|
15.88 |
|
EBITDA (p.s.)
|
3.69 |
|
Qtrly Earnings Growth
|
-28.8 |
|
Operating Cash Flow
|
1,260 (M) |
|
Levered Free Cash Flow
|
892 (M) |
Stock Valuations |
|
PE Ratio
|
49.39 |
|
PEG Ratio
|
4 |
|
Price to Book value
|
4.89 |
|
Price to Sales
|
6.87 |
|
Price to Cash Flow
|
19.79 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
